(BW)(SORIN-GROUP)(SRN.MI) Sorin集团在曼海姆心脏病学会议上强调创新性起搏技术在避免不必要的心脏起搏方面扮演着关键角色
美国商业新闻2006年4月20日德国曼海姆消息——
Sorin集团从不必要的右心室起搏所带来的风险上打响欧洲意识战
在心律调整治疗开发上处于领先地位的Sorin集团（米兰证交所代码：SRN）心律调整（CRM）业务部，将在4月20日-22日期间于曼海姆举办的第72届德国心脏学会年会上专注于其创新性起搏模式——AAIsafeR(TM)，以及防止右心室过度起搏的极度重要性。Sorin集团将在大会开幕当天举办的座谈会上探讨其最新技术。同时在该次座谈会上，Sorin集团还将通过提醒医师不必要的右心房起搏所带来的风险，来拉开其欧洲意识战的帷幕。
若干临床研究表明：通过心脏植入式设备进行不必要的右心室起搏将显著增加病人引发心力衰竭（HF）和房颤（AF）的风险。心力衰竭和房颤是两种在病人支出大量医疗保健系统费用的同时还会引发致命危险的心脏病。
为了回应这一增长的迹象，Sorin集团已开发出一套独特的起搏模式，也就是通过提高病人自然电导能力（AV 传导）来避免不必要的右心室起搏而设计的AAIsafeR模式。通过对AV传导进行规律性的监控，AAIsafeR起搏能够在必要时实现从生理性心房（AAI）刺激到右心房起搏（DDD）功能的自动切换，例如仅当正常AV传导没有发生或者发生过程太慢时，结果导致心脏内自然电路的阻滞（AV阻滞）。
根据AV传导的损害程度我们可将AV阻滞分为三类，第一类最倾向于良性，而第三类最倾向于恶性。AAIsafeR是当前能够通过仅在需要时才提供右心室起搏（DDD）来调整各种心脏传导阻滞的唯一可用模式。AAIsafeR同时也会针对夜间和在锻炼时发生的传导紊乱做出响应，从而实现病人舒适与安全性的最大化。
AAIsafeR起搏模式能将不必要的心房起搏降低到0.1%（1），这一前所未有的成绩使得心力衰竭和房颤的治疗风险以及病人死亡率在医疗所有心脏传导阻时得到很大程度的降低。预计接受双腔指示的起搏器使用病人中有60%将能获益于AAIsafeR。
就职于慕尼黑（德国）德国心脏中心并将在曼海姆年会上演讲的Christof Kolb博士推断道：“由于可支持各种条件下的内在心室导电，AAIsafeR起搏模式将有潜力成为大多数双腔起搏器和心律转复除颤（ICD）治疗患者的医疗金准。”
Sorin集团目前正派遣心脏病专家和电生理学专家对德国各地的一批工作会进行指导，并将其作为欧洲意识战的一部分，来提醒医师避免不必要的右心室起搏的重要性。
Sorin集团心律调整业务总裁Michael Zwick进一步证实道：“对Sorin来说，面向医师全面告知避免右心房过度起搏所带来的积极效应是十分重要的。AAIsafeR是Sorin集团心律调整部门承诺为医师提供确保病人安全与舒适最大化的解决方案的例证。我们位于德国各地工作会的积极反馈已显示出了医师在接受这一意识战和理解其重要性上体现出的积极态度。”
Sorin集团：
Sorin集团心律调整业务部设计并生产植入式起搏器和心律转复除颤（ICD）设备，导联及Holter设备，并在全球范围内营销这些产品。
Sorin集团（路透代码： SORN.MI)是开发心脏手术医疗技术方面的一家世界领先企业，为心律控制、介入性心脏病学以及慢性肾病的治疗提供创新性疗法。Sorin集团的公司包括：Dideco、CarboMedics、COBE Cardiovascular、Stockert, Mitroflow、ELA Medical、Sorin Biomedica、Bellco和Soludia。Sorin集团拥有4700多名员工，他们在世界各地80多个国家内的设施里工作，为超过5000个公立和私营治疗中心服务。
欲了解更多信息请访问我们的网站：
www.sorin.com
参考：
（1）在具有内在导电性的起搏器使用病人方面。SaveR研究的结果，上市前临床研究，2004年9月：起博器数据储存的累计百分比起博。在具有内在导电性的心律转复除颤（ICD）设备使用病人方面，AAIsafeR将心室起搏降低到0.2%。
内部临床报告发布。
联系方式：心律调整业务部 Fred Hrkac，+33-1-46013362 fred.hrkac@sorin.com 或者 投资者关系部 Marilena Giavara，+44-20-70038730 marilena.giavara@sorin.com 或者 通信与行业事务部 Francesca Caprari，+39-02-6332322 francesca.caprari@sorin.com
(BW)(SORIN-GROUP)(SRN.MI) Sorin Group Stresses Key Role of Innovative Pacing Technology in Avoiding Unnecessary Ventricular Pacing at Mannheim Cardiology Congress
MANNHEIM, Germany--(BUSINESS WIRE)--April 20, 2006--
Sorin Group Begins European Awareness Campaign on the Risks
Associated with Unnecessary Pacing of the Right Ventricle
The Sorin Group (MIL:SRN) Cardiac Rhythm Management (CRM) Business Unit, a leader in the development of cardiac rhythm management therapies, will focus on its innovative pacing mode, AAIsafeR(TM), and on the utmost importance of preventing over-pacing of the heart’s right ventricle at the 72th annual meeting of the German Society of Cardiology in Mannheim from April 20th to April 22rd. Sorin Group will be discussing its latest technology during a symposium on the opening day. This symposium concurs with a European awareness campaign launched by Sorin Group to alert physicians on the risks associated with unnecessary ventricular pacing.
Several clinical studies have demonstrated that unnecessary right ventricular pacing from cardiac implantable devices significantly increases the risk of patients developing heart failure (HF) and atrial fibrillation (AF). HF and AF are two cardiac diseases that can prove fatal to patients while placing a heavy cost burden on healthcare systems.
In response to this growing evidence, Sorin Group has developed a unique pacing mode, AAIsafeR, which is designed to avoid unnecessary ventricular pacing by promoting the patient’s natural electrical conduction (AV conduction). By regularly monitoring AV conduction, AAIsafeR pacing can automatically switch from physiological atrial-based (AAI) stimulation to right ventricular pacing (DDD) when necessary, i.e. only when normal AV conduction does not occur or occurs too slowly, causing blocks in the heart’s natural electrical pathway (AV blocks).
AV blocks are classified into three categories according to the level of AV conduction impairment, first degree being the most benign and third degree the most severe form. AAIsafeR is the only mode currently available that manages all types of heart blocks by delivering right ventricular pacing (DDD) only when needed. AAIsafeR also responds to conduction disorders occurring at night and to those occurring while exercising, thus allowing maximum comfort and safety for patients.
AAIsafeR pacing mode reduces unnecessary ventricular pacing to 0.1%(1), an unprecedented performance which significantly reduces risks of HF hospitalization, AF and mortality for patients while treating all heart blocks. It is estimated that 60% of pacemaker patients with dual-chamber indications could benefit from AAIsafeR.
"Because it favors intrinsic atrioventricular conduction in all situations, AAIsafeR pacing mode has the potential to become a gold-standard therapy for the vast majority of dual-chamber pacemaker and ICD patients," concluded Dr. Christof Kolb from the German Heart Center in Munich (Germany), a speaker at the Mannheim Congress.
Sorin Group is currently conducting a series of workshops with cardiologists and electrophysiologists throughout Germany as part of a European awareness campaign to alert them on the importance of avoiding unnecessary right ventricular pacing.
Michael Zwick, Sorin Group’s CRM Business Director in Germany, confirmed that "it is important for Sorin Group to fully inform physicians on the positive effects of avoiding right ventricular over-pacing. AAIsafeR exemplifies Sorin Group CRM commitment to provide physicians with solutions that ensure maximum safety and comfort for patients. Positive feedback to our workshops throughout Germany indicates that physicians are receptive to the campaign and understand its importance".
Sorin Group:
Sorin Group CRM Business Unit designs and manufactures implantable pacemakers and ICDs, leads and Holter equipment and markets them worldwide.
Sorin Group (Reuters code: SORN.MI), a world leader in the development of medical technologies for cardiac surgery, offers innovative therapies for cardiac rhythm dysfunctions, interventional cardiology and the treatment of chronic kidney diseases. Sorin Group includes: Dideco, CarboMedics, COBE Cardiovascular, Stockert, Mitroflow, ELA Medical, Sorin Biomedica, Bellco and Soludia. Sorin Group has more than 4,700 employees working at facilities in more than 80 countries throughout the world to serve over 5,000 public and private treatment centers.
For additional information, please visit our website:
www.sorin.com
Reference:
(1) In pacemaker patients with intrinsic conduction. Results of SaveR study, premarket clinical study, September 2004: cumulative percent pacing stored in the pacemaker data. In ICD patients with intrinsic conduction AAIsafeR reduces ventricular pacing to 0.2%.
Internal clinical release report.
CONTACT: CRM Business Unit Fred Hrkac, +33-1-46013362 fred.hrkac@sorin.com or Investor Relations Marilena Giavara, +44-20-70038730 marilena.giavara@sorin.com or Communications & Industry Affairs Francesca Caprari, +39-02-6332322 francesca.caprari@sorin.com
